Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
172.1 USD | +0.45% | +3.34% | +11.07% |
06-20 | AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis | MT |
06-20 | US FDA proposes to remove switching study requirement for biosimilars | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.07% | 304B | |
+51.99% | 798B | |
-5.72% | 356B | |
+18.94% | 328B | |
+16.96% | 244B | |
+2.25% | 227B | |
+11.15% | 216B | |
+7.59% | 166B | |
-3.65% | 157B | |
-1.84% | 118B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate